Hb A2 Blood Test: What High or Low Levels Mean

Hemoglobin A2 is a minor fraction of the hemoglobin in your red blood cells, normally making up roughly 2 to 3.3 percent of the total. A blood test measuring this fraction matters mainly because an elevated level is the single most reliable laboratory marker for beta-thalassemia trait, while an unexpectedly low level can point to iron deficiency, alpha-thalassemia, or rarer genetic conditions. The test sounds obscure, but it sits at the center of carrier screening programs worldwide, and getting the interpretation right depends on understanding a surprisingly long list of things that can push the number up or down.

What Counts as Normal, High, or Low

In a healthy adult, HbA2 accounts for about 2.0 to 3.3 percent of total hemoglobin.¹ Labs usually flag anything above 3.5 percent as elevated and anything below about 2.0 percent as low, though exact cutoffs vary slightly by instrument and institution. The range between roughly 3.3 and 3.5 percent is considered borderline, and that gray zone causes real diagnostic headaches, as we’ll see.

Because HbA2 is such a small slice of total hemoglobin, even modest shifts of a fraction of a percent matter clinically. A result of 4.5 percent versus 3.0 percent can be the difference between a beta-thalassemia carrier diagnosis and a clean bill of health. That makes anything that artificially nudges the number, whether iron status, thyroid function, or a co-inherited gene variant, genuinely important to track.

What Elevated HbA2 Usually Means

The main reason doctors order an HbA2 measurement is to check for beta-thalassemia trait. People who carry one copy of a beta-thalassemia mutation typically show HbA2 levels between about 4.0 and 8.0 percent.¹ Beta-thalassemia trait on its own usually causes mild or no symptoms. Red blood cells tend to be smaller than average and there may be a slight drop in hemoglobin, but most carriers go through life unaware of the condition unless they are tested.

The reason HbA2 rises in these carriers is straightforward. When one beta-globin gene is underperforming, the body compensates by producing relatively more delta-globin chains, the building blocks of HbA2. The result is a measurable bump in the HbA2 fraction that clinicians can detect with routine hemoglobin analysis.

Carrier status matters most when two carriers plan to have children together. If both parents carry beta-thalassemia trait, each pregnancy has a one-in-four chance of producing a child with beta-thalassemia major, a serious condition requiring lifelong transfusions. That risk is why premarital and prenatal screening programs in Mediterranean, Middle Eastern, South Asian, and Southeast Asian populations lean heavily on HbA2 measurement as a first-line tool.

HbA2 is also used to help distinguish sickle cell disease from sickle/beta-thalassemia. In the literature, an HbA2 above 3.5 percent in someone with predominantly hemoglobin S favors a diagnosis of HbS/beta-thalassemia, while a level below 3.5 percent leans toward sickle cell anemia.² This distinction affects prognosis and treatment, so the number carries real clinical weight beyond thalassemia screening alone.

Non-Genetic Reasons HbA2 Can Be Elevated

Beta-thalassemia trait is the most common explanation for a high HbA2, but it is not the only one. Thyroid hormones appear to influence the expression of delta-globin chains. Research comparing people with untreated hyperthyroidism to healthy controls found that the hyperthyroid group had a higher mean HbA2 level, around 3.2 percent, compared to about 2.5 percent in healthy controls. After treatment brought thyroid function back to normal, HbA2 levels dropped.³ The effect is modest, but in someone whose baseline HbA2 sits near the upper end of normal, an overactive thyroid could potentially push the number past the diagnostic threshold and trigger an unnecessary thalassemia workup.

Vitamin B12 deficiency has also been reported to raise HbA2 slightly in isolated cases, though this is uncommon. A study looking at patients with B12 or folate deficiency found that HbA2 levels were usually normal, with only a few B12-deficient patients showing a slight elevation that returned to normal once they received B12 therapy.⁴ So B12 deficiency is more of a rare footnote than a routine concern, but it is worth mentioning because it occasionally shows up in clinical practice and can cause a brief scare.

What Low HbA2 Levels Suggest

An HbA2 that comes back below about 2.0 percent raises a different set of questions. The three most common explanations are iron deficiency, alpha-thalassemia, and delta-globin gene mutations.

Alpha-thalassemia trait lowers HbA2 because it reduces the availability of alpha-globin chains, which are needed to build HbA2 (remember, HbA2 is made of two alpha chains paired with two delta chains). With fewer alpha chains to go around, less HbA2 gets assembled. Studies have found that individuals with alpha-thalassemia trait have a mean HbA2 that is modestly but consistently lower than people without the trait, about 2.44 percent versus 2.57 percent in one cohort.⁵ The difference sounds tiny, and individually it often is. But it becomes clinically meaningful when alpha-thalassemia occurs alongside beta-thalassemia trait, because it can pull HbA2 down into the normal range and hide the beta-thalassemia diagnosis.

Delta-globin gene mutations are another cause. These mutations impair production of the delta chain directly, so HbA2 drops. In one investigation of 33 patients with unexplained low HbA2, 20 turned out to carry a delta-globin gene mutation, while the remainder had alpha-thalassemia defects, iron depletion, or both.⁶ A separate study covering a broader set of cases with low HbA2 also identified delta-globin mutations in the majority, and the authors emphasized that this can lead to misdiagnosis when someone happens to carry both a delta mutation and a beta-thalassemia mutation.⁷ In those people, the delta mutation drags HbA2 down while the beta-thalassemia mutation would normally push it up, and the two effects can cancel each other out, leaving a deceptively normal result.

Delta-beta thalassemia is a rarer condition worth knowing about. People who are heterozygous for delta-beta thalassemia typically have elevated fetal hemoglobin (HbF) in the range of 5 to 20 percent, with normal or reduced HbA2 and small red blood cells. In the homozygous form, HbF climbs even higher while HbA2 stays low.⁸ If your lab report shows a high HbF alongside a low HbA2 and small red cells, this combination is the classic pointer toward delta-beta thalassemia rather than a standard beta-thalassemia trait.

The Iron Deficiency Problem

Iron deficiency deserves its own discussion because it is the most practically important confounder in HbA2 testing. Iron deficiency lowers HbA2, and because iron deficiency is extremely common worldwide, it regularly collides with thalassemia screening. The concern is real: in a large premarital screening study of over 1,300 people, those with iron deficiency had a mean HbA2 about 0.2 percentage points lower than those without iron deficiency. The authors estimated that about 2.6 percent of the screened population was at genuine risk of a false-negative beta-thalassemia screen because of iron’s suppressive effect on HbA2.⁹

A shift of 0.2 percent might not sound like much, but consider someone who is a beta-thalassemia carrier with a true HbA2 of 3.7 percent. Iron deficiency could push that reading down to around 3.5 or even below, right on the border of detection. In a subset of iron-deficient individuals who were given iron repletion and then retested, HbA2 levels rose significantly, unmasking previously hidden beta-thalassemia trait in some cases.⁹

Even among confirmed beta-thalassemia carriers who happen to be iron deficient, the HbA2 is generally still above the diagnostic threshold, though it runs lower than in non-iron-deficient carriers. A pediatric study found that the median HbA2 in iron-deficient carriers was about 4.1 percent compared to 4.9 percent in carriers without iron deficiency.¹⁰ Most of those children still fell above the 3.5 percent diagnostic line, but the gap was narrowed enough to create real diagnostic anxiety, especially if other suppressive factors like alpha-thalassemia were also in play.

The practical takeaway for anyone getting tested: if your HbA2 comes back borderline or unexpectedly normal, and you have small red blood cells or signs of low iron, your doctor should check your iron stores before concluding the screen is truly negative. Correcting the iron deficiency and retesting is a standard recommendation in this situation.

The Borderline Zone

HbA2 values between roughly 3.3 and 3.5 percent occupy an awkward diagnostic no-man’s-land. A large study that examined over 200 individuals with borderline HbA2 levels found that about 82 percent of them had an identifiable genetic or acquired explanation. Among those with an identified cause, the vast majority, about 88 percent, were beta-thalassemia carriers. Some of those carriers also had co-existing iron deficiency or co-inherited alpha or delta-globin defects that had pulled their HbA2 into the borderline range.¹¹

This means borderline HbA2 is not something to shrug off. More often than not, it signals an underlying carrier state that has been partially masked by one or more complicating factors. Clinicians typically follow up borderline results by checking iron status, red blood cell size and hemoglobin content, family history, and sometimes genetic testing to look for alpha or delta-globin mutations. Combining red cell indices with hemoglobin analysis improves diagnostic accuracy substantially compared to relying on any single test.¹¹

How the Test Is Done

Two laboratory methods dominate HbA2 measurement: high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE). Both separate hemoglobin fractions so each one can be quantified, but they do it differently: HPLC separates by how tightly hemoglobin variants stick to a column, while CZE separates by how fast they migrate in an electric field. In routine samples without unusual hemoglobin variants, the two methods correlate well, though CZE tends to read slightly higher, with a bias of about 0.1 percent.¹²

Where the methods diverge more noticeably is in samples that contain structural hemoglobin variants like hemoglobin S, C, D, or E. Some variants co-migrate with HbA2 on certain HPLC systems, artificially inflating the reading. CZE handles these variants more cleanly in many cases, giving a more accurate HbA2 value for people with sickle trait, hemoglobin E trait, or hemoglobin D trait.¹³ For that reason, many reference labs use both methods in combination: HPLC as the primary workhorse and CZE as a confirmatory or complementary tool when a variant is suspected.

Standardization has been an ongoing challenge. Different instruments, calibrators, and reagents can produce slightly different HbA2 values from the same blood sample, which is a problem when the diagnostic threshold is a single fixed number. International efforts led by the IFCC have worked to develop certified reference materials and a reference measurement procedure to reduce this variability across laboratories.¹⁴ Progress has been steady, but instrument-to-instrument variation has not been fully eliminated, which is one more reason borderline results should be interpreted cautiously rather than taken at face value.

HbA2 in Newborns and Young Children

HbA2 levels in newborns are not the same as in adults, and this matters for timing screening correctly. At birth, most of a baby’s hemoglobin is fetal hemoglobin (HbF), and HbA2 is very low. As fetal hemoglobin is gradually replaced by adult hemoglobin types over the first months of life, HbA2 rises. The most rapid increases happen before six months of age, but levels continue to climb and may not fully stabilize until after the third year.¹⁵

This means that testing HbA2 in a very young child, especially under six months old, can produce misleadingly low results even if the child carries beta-thalassemia trait. In clinical practice, newborn screening programs for hemoglobin disorders focus on detecting hemoglobin S, C, and other structural variants rather than on HbA2 quantification. Definitive carrier testing based on HbA2 is typically deferred until the child is older, often after age one or two, when the hemoglobin profile has matured enough to be reliably interpreted.

When Screening Programs Miss Carriers

Large-scale thalassemia screening programs rely on a simple initial filter: check red blood cell size (MCV) and then, if the cells are small, measure HbA2. The strategy works well for most beta-thalassemia carriers, whose red cells are almost always small and whose HbA2 is almost always elevated. But it is less reliable for alpha-thalassemia carriers, a substantial fraction of whom have normal-sized red cells. In one prenatal screening cohort, about a third of alpha-thalassemia carriers had an MCV of 80 fL or above, meaning they would have been missed by a screening program that used MCV as the only gateway to further testing.¹⁶

For beta-thalassemia carriers the miss rate was much lower, with about 12.5 percent having a normal MCV in the same cohort, but it was not zero.¹⁶ Add the confounding effects of iron deficiency, alpha-thalassemia co-inheritance, or delta-globin mutations discussed earlier, and it becomes clear why some experts argue that genetic testing should play a larger role in screening rather than relying solely on hematologic indices and HbA2 levels.

Why the Delta-Globin Gene Has Stuck Around

HbA2 makes up such a small proportion of total hemoglobin that you might wonder why it exists at all. The delta-globin gene that encodes it could easily have become a nonfunctional relic over evolutionary time, and in many non-primate mammals, that is roughly what happened. But in primates, the delta-globin gene has been remarkably well preserved. An analysis across primate lineages found strong evolutionary constraints on the delta-globin gene over at least 65 million years, with very low rates of change that suggest the gene is doing something important enough that mutations to it are weeded out by natural selection.¹⁷

The leading hypothesis is that the conservation is less about HbA2 carrying oxygen and more about a regulatory role. The delta-globin gene sits in a cluster with the other beta-like globin genes, and it appears to contain regulatory elements involved in the developmental switch from fetal to adult hemoglobin. In other words, the gene might matter not so much for the protein it produces as for the signals it sends to its neighboring genes. An earlier analysis of the spider monkey delta-globin gene reached a similar conclusion, noting that the low rate of protein-changing mutations across primates hints at an as-yet-unknown physiological importance for HbA2.¹⁸ For now, the precise function of HbA2 beyond its diagnostic utility remains one of those quietly unresolved questions in human biology.

1
PubMed Central. The importance of hemoglobin A2 determination
2
PubMed Central. Difficulties in the diagnosis of HbS/beta thalassemia: Really a mild disease?
3
PubMed. Influence of thyroid status on hemoglobin A2 expression
4
PubMed Central. Haemoglobin A2 levels in vitamin B12 and folate deficiency
5
PubMed Central. Hemoglobin A2 Lowered by Iron Deficiency and α-Thalassemia: Should Screening Recommendation for β-Thalassemia Change?
6
PubMed. Known and new δ-globin gene mutations and other factors influencing Hb A2 measurement in the Omani population
7
Haematologica. Known and new delta globin gene mutations and their diagnostic significance
8
British Journal of Biomedical Science. Homozygous Delta-Beta Thalassaemia With Alpha Thalassaemia and Erythrocytosis- a Rare Case Report
9
International Journal of Pharmaceutical Quality Assurance. Impact of Iron Deficiency on HBA2 Levels and its Implications in Thalassemia Trait Detection
10
PubMed Central. HbA2 levels in children with β-thalassemia trait associated with iron deficiency: A perspective for pediatricians
11
Haematologica. Unresolved laboratory issues of the heterozygous state of β-thalassemia: a literature review
12
PubMed Central. Comparison of Capillary Zone Electrophoresis with High-pressure Liquid Chromatography in the Evaluation of Hemoglobinopathies
13
Blood. Comparison of High Resolution HPLC with Capillary Zone Electrophoresis in Hemoglobin A2 Measurement
14
PubMed. Standardization of hemoglobin A(2) and hemoglobin F: Achievements and perspectives
15
PubMed. The development of haemoglobin A2 in normal negro infants and in sickle cell disease
16
ScienceDirect (Journal of the Formosan Medical Association). Enhancing thalassemia carrier detection: Advancing genetic screening strategies in prenatal care
17
PubMed Central. Distinctive patterns of evolution of the δ-globin gene (HBD) in primates
18
Molecular Biology and Evolution. The structure and evolution of the spider monkey delta-globin gene